Cargando…

PROTACs in the Management of Prostate Cancer

Cancer treatments with targeted therapy have gained immense interest due to their low levels of toxicity and high selectivity. Proteolysis-Targeting Chimeras (PROTACs) have drawn special attention in the development of cancer therapeutics owing to their unique mechanism of action, their ability to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yedla, Poornachandra, Babalghith, Ahmed O., Andra, Vindhya Vasini, Syed, Riyaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10179857/ https://www.ncbi.nlm.nih.gov/pubmed/37175108 http://dx.doi.org/10.3390/molecules28093698

Ejemplares similares

PROTACs in gastrointestinal cancers
por: Chen, Yu, et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Small-Molecule PROTACs for Cancer Immunotherapy
por: Liu, Zefan, et al.
Publicado: (2022)

Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast Cancer
por: Badiginchala, Revathi, et al.
Publicado: (2023)

A Study of Clinical Profile of Primary Extranodal Lymphomas in a Tertiary Care Institute in South India
por: Pai, Ananth, et al.
Publicado: (2017)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

A narrative review of proteolytic targeting chimeras (PROTACs): future perspective for prostate cancer therapy
por: Chen, Xuanrong, et al.
Publicado: (2021)

The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019)

PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022)

Antiviral PROTACs: Opportunity borne with challenge
por: Liang, Jinsen, et al.
Publicado: (2023)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
por: Liu, Xuelian, et al.
Publicado: (2023)

PROTACs: A novel strategy for cancer drug discovery and development
por: Han, Xin, et al.
Publicado: (2023)

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
por: Kelm, Jeremy M., et al.
Publicado: (2023)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

PROTACs: great opportunities for academia and industry
por: Sun, Xiuyun, et al.
Publicado: (2019)

Recent Advances in PROTAC-Based Antiviral Strategies
por: Ahmad, Haleema, et al.
Publicado: (2023)

Novel approaches for the rational design of PROTAC linkers
por: Zagidullin, Almaz, et al.
Publicado: (2020)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

A Rare Case of Complete Cryptophthalmos and Suspected Fraser’s Syndrome in a Female Neonate
por: Ramadugu, Rithika, et al.
Publicado: (2023)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

MicroRNAs as a therapeutic target in IgA nephropathy in Indian population
por: Tripathy, Anindita, et al.
Publicado: (2023)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
por: Xiao, Mingchao, et al.
Publicado: (2022)

Recent Advances in PROTACs for Drug Targeted Protein Research
por: Yao, Tingting, et al.
Publicado: (2022)

An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022)

Editorial: PROTACs: Targeted therapies for cancer treatment
por: Tabassum, Sobia
Publicado: (2023)

Editorial: PROTACs: Targeted therapies for cancer treatment
por: Tabassum, Sobia
Publicado: (2023)

PROTACs: The Future of Leukemia Therapeutics
por: Anwar, Zubair, et al.
Publicado: (2022)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Current strategies for the design of PROTAC linkers: a critical review
por: Troup, Robert I., et al.
Publicado: (2020)

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019)

Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
por: Kim, Hanbyeol, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_roibkq6mlldo48bfilrno3pue0